LIVE
MMM
3M Company · Diversified Industrial
$160.60
+7.53% this month
VERSUS
⟷
COMPARE
EMR
Emerson Electric Co. · Diversified Industrial Automation
$150.66
+15.32% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
MMM
1
EMR
4
Comparison scoreboard
EMR LEADS 4/5AI Score
MMM 40.5
EMR ✓50.6
1Y Return
MMM +12.93%
EMR ✓+18.29%
Fwd P/E
MMM ✓16.97
EMR 21.02
Target Up.
MMM +6.46%
EMR ✓+8.50%
Op. Margin
MMM 23.32%
EMR ✓24.24%
Metrics last refreshed: 6/22/2026
Quick take
MMM vs EMR Stock Comparison: AI Score, Valuation, Performance and Upside
MMM and EMR are both industrial conglomerates in transformation. 3M has streamlined by spinning off healthcare (Solventum) while managing significant PFAS and earplug litigation. Emerson has divested climate technology and acquired NI to focus on industrial automation. Emerson's transformation toward software-intensive automation has been better received by the market; 3M's litigation overhang continues to weigh on its valuation despite the Solventum separation.
MMM vs EMR — 3M (the diversified technology company streamlining post-Solventum healthcare spinoff while managing PFAS chemical and combat arms earplug litigation legacy, with patents across adhesives, films, and electronics materials) versus Emerson Electric (the industrial automation specialist refocused on process control, industrial software through AspenTech, and test/measurement through National Instruments acquisition).
Live analysis · updated 6/22/2026
EMR holds the edge across 4 of 5 key metrics in this comparison. EMR has delivered stronger 1-year price return (+18.29% vs +12.93%), though MMM trades at the lower forward P/E (16.97x vs 21.02x). EMR leads on both revenue growth (2.90%) and operating margin (24.24%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies similar upside for both: +6.46% for MMM and +8.50% for EMR.
Normalized 1Y performance
MMM
EMR
Recent returns
MMM
EMR
Analyst price targets & sentiment
MMM · 18 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.2/5.0)
Price target range
analyst low$100.00
analyst high$184.00
analyst mean$170.97
current price$160.60
+6.5% upside to analyst mean
EMR
Price target range
analyst mean$163.47
current price$150.66
+8.5% upside to analyst mean
Who should consider this stock?
MMM may suit investors who:
- →see 3M's litigation resolution as eventually clearing the overhang — once PFAS and earplug liabilities are more definitively resolved, the remaining 3M industrial business could rerate higher
- →value Post-it and Scotch's consumer brand durability as reliable consumer revenue across economic cycles alongside the industrial portfolio
- →see Solventum spinoff as unlocking value by giving 3M industrial a separate, cleaner financial identity without healthcare segment complexity
- →are comfortable with ongoing litigation uncertainty, PFAS liability not fully quantified, and the post-Solventum strategic identity transition period
EMR may suit investors who:
- →believe Emerson's transformation toward industrial automation software (AspenTech, NI) creates higher-multiple revenue than the prior diversified hardware-focused business
- →see AspenTech's industrial process optimization software as a high-margin SaaS-like revenue stream embedded in critical industrial operations
- →value Emerson's automation focus as aligned with the decade-long industrial automation capital investment cycle — manufacturers investing in reducing labor and improving efficiency
- →are comfortable with cyclical end market exposure (energy, chemicals), automation competition from Honeywell and Siemens, and strategic transition execution risk during NI integration
Performance & AI score
| Metric | MMM | EMR |
|---|---|---|
| AI score | 40.5 | 50.6 |
| AI rank | #1040 | #432 |
| Latest close | $160.60 | $150.66 |
| 1M return | +7.53% | +15.32% |
| 6M return | -0.97% | +14.45% |
| 1Y return | +12.93% | +18.29% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | MMM | EMR |
|---|---|---|
| 1Y ago | $11.27K (+12.7%) started 2025-06-18 | $11.71K (+17.1%) started 2025-06-18 |
| 5Y ago | $13.58K (+35.8%) started 2021-06-21 | $18.85K (+88.5%) started 2021-06-21 |
| 10Y ago | $21.58K (+115.8%) started 2016-06-20 | $46.32K (+363.2%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | MMM | EMR |
|---|---|---|
| Market cap | $83.76B | $84.38B |
| Trailing P/E | 30.94 | 34.88 |
| Forward P/E | 16.97 | 21.02 |
| Price/Sales | 3.19 | N/A |
| EV/Revenue | 3.64 | 5.28 |
| Analyst target | $170.97 | $163.47 |
| Target upside | +6.46% | +8.50% |
Growth, profitability & risk
| Metric | MMM | EMR |
|---|---|---|
| Revenue growth | 1.30% | 2.90% |
| Earnings growth | -39.70% | 27.90% |
| EPS growth | -39.70% | +27.90% |
| FCF margin | +9.28% | +17.87% |
| Operating margin | 23.32% | 24.24% |
| Profit margin | 11.14% | 13.35% |
| ROIC proxy | 71.46% | 12.33% |
| Return on equity | 71.46% | 12.33% |
| Dividend yield | 1.94% | 1.47% |
| Beta | 1.09 | 1.25 |
| Debt/equity | 396.50 | 69.18 |
| Current ratio | 1.59 | 0.87 |
| Quick ratio | 1.06 | 0.59 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
MMM max drawdown19.13%
EMR max drawdown23.74%
MMM max wkly drop7.99%
EMR max wkly drop8.71%
5Y risk snapshot
MMM max drawdown53.34%
EMR max drawdown29.61%
MMM max wkly drop13.89%
EMR max wkly drop15.00%
10Y risk snapshot
MMM max drawdown59.10%
EMR max drawdown50.77%
MMM max wkly drop15.07%
EMR max wkly drop28.66%
Performance metrics by period
| Period | Metric | MMM | EMR |
|---|---|---|---|
| 1Y | Growth | +12.69% | +17.10% |
| CAGR | +12.71% | +17.13% | |
| Sharpe ratio | 0.42 | 0.52 | |
| Max drawdown | 19.13% | 23.74% | |
| Max daily drop | 6.96% | 6.26% | |
| Max wkly drop | 7.99% | 8.71% | |
| 5Y | Growth | +14.88% | +72.66% |
| CAGR | +2.82% | +11.56% | |
| Sharpe ratio | 0.08 | 0.37 | |
| Max drawdown | 53.34% | 29.61% | |
| Max daily drop | 11.03% | 8.65% | |
| Max wkly drop | 13.89% | 15.00% | |
| 10Y | Growth | +51.75% | +256.62% |
| CAGR | +4.26% | +13.57% | |
| Sharpe ratio | 0.12 | 0.43 | |
| Max drawdown | 59.10% | 50.77% | |
| Max daily drop | 12.95% | 18.96% | |
| Max wkly drop | 15.07% | 28.66% |
Business comparison
| Category | MMM | EMR |
|---|---|---|
| Company | 3M Company | Emerson Electric Co. |
| Sector | Industrials | Industrials |
| Industry | Conglomerates | N/A |
| Core business | 3M is a diversified technology company with products across Safety & Industrial (adhesives, personal protective equipment, abrasives), Transportation & Electronics (films, displays, auto parts), Health Care (wound care, dental, filtration), and Consumer (Post-it, Scotch tape, Scotchgard). 3M spun off its healthcare division as Solventum in 2024, focusing the remaining 3M on industrial and electronic products. 3M faces significant legacy litigation from PFAS chemical contamination (military base water contamination, $10.3B settlement) and combat arms earplugs (significant settlements with US veterans). The remaining 3M is streamlining toward automation, advanced materials, and electronics. | Emerson Electric is an automation technology company that has strategically streamlined from a diversified industrial conglomerate to focus on industrial automation and process control software/hardware. Emerson sold its Climate Technologies and other non-core businesses and acquired National Instruments (NI, test and measurement) in 2023. Emerson's focus is now on intelligent automation systems (process control, safety systems, industrial software) for energy, chemicals, food and beverage, and life sciences customers. AspenTech (software, Emerson majority ownership) provides AI-powered industrial process optimization. |
| Investor focus | Investors focus on 3M's litigation resolution progress (PFAS, earplug), Solventum spinoff benefits to remaining 3M, organic revenue growth in the streamlined portfolio, and cost reduction targets. | Investors focus on Emerson's automation software and hardware revenue growth, AspenTech integration value, margin expansion from streamlined portfolio, and capital deployment of divestitures proceeds. |
MMM strengths
- →Innovation culture with 55,000+ patents: 3M's research and development culture has generated a vast patent portfolio spanning adhesives, films, abrasives, and filtration materials
- →Post-it and Scotch tape consumer brand durability: 3M's consumer brands (Post-it, Scotch) have near-universal brand recognition and consistent demand from office, retail, and home use
- →Electronics and semiconductor materials expertise: 3M's advanced materials (optical films for displays, semiconductor interconnect materials) serve the technology supply chain with specialty products difficult to replace
EMR strengths
- →Automation technology focus for secular demand: industrial automation is a major capital investment priority for manufacturers — Emerson's focus on process control and industrial software positions it for the automation spending cycle
- →AspenTech industrial software exposure: Emerson's majority ownership of AspenTech provides exposure to high-margin industrial process optimization software used in energy, chemicals, and food manufacturing
- →National Instruments (NI) acquisition expanding test and measurement: NI's hardware and software for automated testing complements Emerson's industrial automation focus and adds high-R&D technology customers
Risks to watch — MMM
- →PFAS litigation financial overhang: despite the $10.3B water utility settlement, additional PFAS litigation remains possible — the full financial exposure of 3M's legacy chemical liabilities is uncertain
- →Combat arms earplug settlements: 3M has settled a significant number of veterans' hearing damage claims from defective CAEv2 earplugs — ongoing settlement administration creates cash drain
- →Post-Solventum 3M strategic identity: after spinning off healthcare, 3M must demonstrate that the remaining industrial/electronic business can grow independently without the healthcare division's contribution
Risks to watch — EMR
- →Post-divestiture execution proving the automation-focused story: Emerson must demonstrate that the streamlined automation portfolio can grow faster than the prior diversified business — strategic transitions take time to prove out
- →Automation software competition from Honeywell, Siemens, ABB: Emerson competes in industrial automation with well-resourced global competitors — maintaining technology differentiation vs Honeywell and Siemens requires ongoing R&D investment
- →Cyclical end markets (energy, chemicals): Emerson's process automation customers are in cyclical industries — oil and gas capital spending cycles affect Emerson's order rates and revenue
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →